title: Investigation of the vitamin D receptor gene (VDR) and its interaction with protein tyrosine phosphatase, non-receptor type 2 gene (PTPN2) on risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY).
abstract: The present study investigated the association between variants in the vitamin D receptor gene (VDR) and protein tyrosine phosphatase, non-receptor type 2 gene (PTPN2), as well as an interaction between VDR and PTPN2 and the risk of islet autoimmunity (IA) and progression to type 1 diabetes (T1D). The Diabetes Autoimmunity Study in the Young (DAISY) has followed children at increased risk of T1D since 1993. Of the 1692 DAISY children genotyped for VDR rs1544410, VDR rs2228570, VDR rs11568820, PTPN2 rs1893217, and PTPN2 rs478582, 111 developed IA, defined as positivity for GAD, insulin or IA-2 autoantibodies on 2 or more consecutive visits, and 38 IA positive children progressed to T1D. Proportional hazards regression analyses were conducted. There was no association between IA development and any of the gene variants, nor was there evidence of a VDR*PTPN2 interaction. Progression to T1D in IA positive children was associated with the VDR rs2228570 GG genotype (HR: 0.49, 95% CI: 0.26-0.92) and there was an interaction between VDR rs1544410 and PTPN2 rs1893217 (p(interaction)=0.02). In children with the PTPN2 rs1893217 AA genotype, the VDR rs1544410 AA/AG genotype was associated with a decreased risk of T1D (HR: 0.24, 95% CI: 0.11-0.53, p=0.0004), while in children with the PTPN2 rs1893217 GG/GA genotype, the VDR rs1544410 AA/AG genotype was not associated with T1D (HR: 1.32, 95% CI: 0.43-4.06, p=0.62). These findings should be replicated in larger cohorts for confirmation. The interaction between VDR and PTPN2 polymorphisms in the risk of progression to T1D offers insight concerning the role of vitamin D in the etiology of T1D.
authors.affiliation: Colorado School of Public Health, University of Colorado, Aurora, CO, USA.
authors.forename: B
authors.initials: B
authors.lastname: Frederiksen
authors.forename: E
authors.initials: E
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Romanos
authors.forename: A K
authors.initials: AK
authors.lastname: Steck
authors.forename: X
authors.initials: X
authors.lastname: Yin
authors.forename: M
authors.initials: M
authors.lastname: Kroehl
authors.forename: T E
authors.initials: TE
authors.lastname: Fingerlin
authors.forename: H
authors.initials: H
authors.lastname: Erlich
authors.forename: G S
authors.initials: GS
authors.lastname: Eisenbarth
authors.forename: M
authors.initials: M
authors.lastname: Rewers
authors.forename: J M
authors.initials: JM
authors.lastname: Norris
mesh_terms: D001323:Autoantibodies / Q000097:blood; D015551:Autoimmunity / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology / Q000235:genetics* / Q000276:immunology; D018450:Disease Progression; D005260:Female; D005968:Glutamate Decarboxylase / Q000276:immunology; D006801:Humans; D007223:Infant; D007330:Insulin Antibodies / Q000097:blood; D007515:Islets of Langerhans / Q000276:immunology*; D008297:Male; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies; D054578:Protein Tyrosine Phosphatase, Non-Receptor Type 2 / Q000235:genetics*; D018167:Receptors, Calcitriol / Q000235:genetics*; D012307:Risk Factors
chemical_list: D001323:Autoantibodies; C096322:ICA512 autoantibody; D007330:Insulin Antibodies; D018167:Receptors, Calcitriol; C516649:PTPN2 protein, human; D054578:Protein Tyrosine Phosphatase, Non-Receptor Type 2; D005968:Glutamate Decarboxylase; C401141:glutamate decarboxylase 2